Bone Biologics (BBLG) Short term Debt (2014 - 2017)

Bone Biologics (BBLG) has reported Short term Debt for 5 consecutive years, with $12.9 million the latest figure, recorded in Q3 2017.

• In Q3 2017, Short term Debt rose 43.33% year-over-year to $12.9 million; the TTM figure through Sep 2017 stood at $12.9 million (up 43.33% YoY), while the FY2016 annual figure was $1.2 million, down 82.86% from the prior year.
• Short term Debt grew to $12.9 million in Q3 2017 per BBLG's latest filing, from $12.2 million in the prior quarter.
• Across five years, Short term Debt topped out at $12.9 million in Q3 2017 and bottomed at $41300.0 in Q4 2013.
• Historically, Short term Debt has averaged $6.9 million across 5 years, with a median of $7.0 million in 2015.
• Annual changes were most pronounced in 2014 — Short term Debt jumped 12006.54% — and 2016, when it sank 82.86%.
• Bone Biologics' Short term Debt stood at $41300.0 in 2013, then surged by 12006.54% to $5.0 million in 2014, then jumped by 40.0% to $7.0 million in 2015, then tumbled by 82.86% to $1.2 million in 2016, then jumped by 975.0% to $12.9 million in 2017.
• Business Quant data shows BBLG's Short term Debt at $12.9 million in Q3 2017, $12.2 million in Q2 2017, and $12.2 million in Q1 2017.